Fremgangsmåde til oprensning af en prøve af H38C2-antistof

The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BALU, Palani, XIE, Jin, PALANKI, Moorthy Sitharamaiah Suriyanarayana, LAURENT, Olivier Alexandre, HUANG, Jie, LUKSHA, Nicholas Gary, WASZAK, Gregory Allan, LEVIN, Nancy Jane, POZZO, Mark John, FINN, Rory Francis, MARTIN, Joseph Patrick Jr, ANNATHUR, Gopinath Vedachalam, MOSKOWITZ, Haim
Format: Patent
Sprache:dan
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.